A new review published July 17, 2013 in the Journal of Experimental Pharmacology
by Dr. Laurie Doering and colleagues at McMaster University in Canada
Breakthrough advances in potential therapy for FXS followed the discovery of excessive mGluR) signaling in Fragile X brain cells. Many pharmaceutical companies have designed drugs to target this defect. Promising results from animal and clinical studies suggest that mGluR5 antagonists such as AFQ056 from Novartis can successfully correct many of the deﬁcits in Fragile X. This article covers the animal studies performed to date that test the role of AFQ056 to alleviate the phenotypes of FXS.
AFQ056, also known as mavoglurant, is being developed by Novartis for Fragile X, Parkinsons disease, and other disorders.